Provided by Tiger Trade Technology Pte. Ltd.

Global X HealthTech ETF

28.39
+0.09650.34%
Post-market: 28.36-0.0300-0.11%16:15 EDT
Volume:3K
Turnover:78.24K
Market Cap:29.81M
PE:- -
High:28.46
Open:28.40
Low:28.29
Close:28.29
52wk High:33.59
52wk Low:23.00
Shares:1.05M
Float Shares:1.05M
Volume Ratio:0.65
T/O Rate:0.26%
Dividend:0.07
Dividend Rate:0.25%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Gartner Inc. Stock Climbs 5.3%, Outperforms Peers

Dow Jones
·
Yesterday

Hims & Hers Health Price Target Announced at $32.00/Share by JP Morgan

Dow Jones
·
Sep 11

Tempus AI to build multimodal whole-genome dataset for AI-driven healthcare

TIPRANKS
·
Sep 11

BofA Adjusts Price Target on Oscar Health to $28 From $25

MT Newswires Live
·
Sep 11

Tempus AI Launches Effort to Build 100,000 Whole-Genome Dataset Linked to Clinical Outcomes

Reuters
·
Sep 11

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

THOMSON REUTERS
·
Sep 11

Tempus AI, - General Availability of Dataset Planned for Mid-2027

THOMSON REUTERS
·
Sep 11

Centene Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

DexCom Director Glenn S. Boehnlein Files Initial Beneficial Ownership Statement

Reuters
·
Sep 11

Dexcom Names Former Stryker CFO Glenn Boehnlein to Board

Reuters
·
Sep 11

Dexcom Appoints Glenn Boehnlein to Board of Directors

THOMSON REUTERS
·
Sep 11

IQVIA Announces Pricing of Senior Notes

THOMSON REUTERS
·
Sep 10

Iqvia. - Notes to Bear 6.375% Interest, Payable Semi-Annually from March 15, 2027

THOMSON REUTERS
·
Sep 10

Labcorp Holdings Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 10

Tempus AI awarded up to $9.5M from ARPA-H for autonomous AI in cardiology

TIPRANKS
·
Sep 10

Tempus AI Wins up to $9.5 Million ARPA-H Advocate Award for Autonomous Heart Failure Agent

Reuters
·
Sep 10

Tempus Secures up to $9.5 Million in Arpa-H Advocate Funding to Deploy First Autonomous AI in Cardiology

THOMSON REUTERS
·
Sep 10

IQVIA backs real world pegcetacoplan study in rare kidney disease

TIPRANKS
·
Sep 10

Tempus AI Initiated at Neutral by UBS

Dow Jones
·
Sep 09

UBS Initiates Coverage on Tempus AI With Neutral Rating, $70 Price Target

MT Newswires Live
·
Sep 09